Literature DB >> 18775121

Pharmacologic modulation of ACE2 expression.

María José Soler1, Clara Barrios, Raymond Oliva, Daniel Batlle.   

Abstract

Angiotensin-converting enzyme 2 (ACE2) is an enzymatically active homologue of angiotensin-converting enzyme that degrades angiotensin I, angiotensin II, and other peptides. Recent studies have shown that under pathologic conditions, ACE2 expression in the kidney is altered. In this review, we briefly summarize recent studies dealing with pharmacologic interventions that modulate ACE2 expression. ACE2 amplification may have a potential therapeutic role for kidney disease and hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18775121      PMCID: PMC7089438          DOI: 10.1007/s11906-008-0076-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  43 in total

1.  Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies.

Authors:  G Valdés; L A A Neves; L Anton; J Corthorn; C Chacón; A M Germain; D C Merrill; C M Ferrario; R Sarao; J Penninger; K B Brosnihan
Journal:  Placenta       Date:  2005-04-25       Impact factor: 3.481

2.  Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.

Authors:  S Yamagishi; M Takeuchi
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

3.  Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

Authors:  Minghao Ye; Jan Wysocki; Josette William; Maria José Soler; Ivan Cokic; Daniel Batlle
Journal:  J Am Soc Nephrol       Date:  2006-10-04       Impact factor: 10.121

4.  Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.

Authors:  Koichi Yamamoto; Mitsuru Ohishi; Tomohiro Katsuya; Norihisa Ito; Masashi Ikushima; Masaharu Kaibe; Yuji Tatara; Atsushi Shiota; Sumio Sugano; Satoshi Takeda; Hiromi Rakugi; Toshio Ogihara
Journal:  Hypertension       Date:  2006-02-27       Impact factor: 10.190

5.  Developmental expression of ACE2 in the SHR kidney: a role in hypertension?

Authors:  C Tikellis; M E Cooper; K Bialkowski; C I Johnston; W C Burns; R A Lew; A I Smith; M C Thomas
Journal:  Kidney Int       Date:  2006-05-17       Impact factor: 10.612

6.  Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.

Authors:  Carlos M Ferrario; Jewell Jessup; Patricia E Gallagher; David B Averill; K Bridget Brosnihan; E Ann Tallant; Ronald D Smith; Mark C Chappell
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

Review 7.  New aspects of the renin-angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy.

Authors:  Daniel Batlle; María José Soler; Jan Wysocki
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-05       Impact factor: 2.894

8.  Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents.

Authors:  José A Hernández Prada; Anderson J Ferreira; Michael J Katovich; Vinayak Shenoy; Yanfei Qi; Robson A S Santos; Ronald K Castellano; Andrew J Lampkins; Vladimir Gubala; David A Ostrov; Mohan K Raizada
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.

Authors:  Jun Agata; Nobuyuki Ura; Hideaki Yoshida; Yasuyuki Shinshi; Haruki Sasaki; Masaya Hyakkoku; Shinya Taniguchi; Kazuaki Shimamoto
Journal:  Hypertens Res       Date:  2006-11       Impact factor: 3.872

10.  Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.

Authors:  Anna de Lang; Albert D M E Osterhaus; Bart L Haagmans
Journal:  Virology       Date:  2006-07-24       Impact factor: 3.616

View more
  24 in total

1.  Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19.

Authors:  Saskia Trump; Soeren Lukassen; Markus S Anker; Robert Lorenz Chua; Johannes Liebig; Loreen Thürmann; Victor Max Corman; Marco Binder; Jennifer Loske; Christina Klasa; Teresa Krieger; Bianca P Hennig; Marey Messingschlager; Fabian Pott; Julia Kazmierski; Sven Twardziok; Jan Philipp Albrecht; Jürgen Eils; Sara Hadzibegovic; Alessia Lena; Bettina Heidecker; Thore Bürgel; Jakob Steinfeldt; Christine Goffinet; Florian Kurth; Martin Witzenrath; Maria Theresa Völker; Sarah Dorothea Müller; Uwe Gerd Liebert; Naveed Ishaque; Lars Kaderali; Leif-Erik Sander; Christian Drosten; Sven Laudi; Roland Eils; Christian Conrad; Ulf Landmesser; Irina Lehmann
Journal:  Nat Biotechnol       Date:  2020-12-24       Impact factor: 54.908

2.  Abnormalities of angiotensin regulation in postural tachycardia syndrome.

Authors:  Hossam I Mustafa; Emily M Garland; Italo Biaggioni; Bonnie K Black; William D Dupont; David Robertson; Satish R Raj
Journal:  Heart Rhythm       Date:  2011-01-22       Impact factor: 6.343

3.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.

Authors:  Renato D Lopes; Ariane V S Macedo; Pedro G M de Barros E Silva; Renata J Moll-Bernardes; Tiago M Dos Santos; Lilian Mazza; André Feldman; Guilherme D'Andréa Saba Arruda; Denílson C de Albuquerque; Angelina S Camiletti; Andréa S de Sousa; Thiago C de Paula; Karla G D Giusti; Rafael A M Domiciano; Márcia M Noya-Rabelo; Alan M Hamilton; Vitor A Loures; Rodrigo M Dionísio; Thyago A B Furquim; Fábio A De Luca; Ítalo B Dos Santos Sousa; Bruno S Bandeira; Cleverson N Zukowski; Ricardo G G de Oliveira; Noara B Ribeiro; Jeffer L de Moraes; João L F Petriz; Adriana M Pimentel; Jacqueline S Miranda; Bárbara E de Jesus Abufaiad; C Michael Gibson; Christopher B Granger; John H Alexander; Olga F de Souza
Journal:  JAMA       Date:  2021-01-19       Impact factor: 56.272

4.  Outcome prediction during an ICU surge using a purely data-driven approach: A supervised machine learning case-study in critically ill patients from COVID-19 Lombardy outbreak.

Authors:  Massimiliano Greco; Giovanni Angelotti; Pier Francesco Caruso; Alberto Zanella; Niccolò Stomeo; Elena Costantini; Alessandro Protti; Antonio Pesenti; Giacomo Grasselli; Maurizio Cecconi
Journal:  Int J Med Inform       Date:  2022-06-02       Impact factor: 4.730

Review 5.  ACE2, a promising therapeutic target for pulmonary hypertension.

Authors:  Vinayak Shenoy; Yanfei Qi; Michael J Katovich; Mohan K Raizada
Journal:  Curr Opin Pharmacol       Date:  2011-01-05       Impact factor: 5.547

6.  Renin-Angiotensin-Aldosterone System Inhibitors and the Risk of AKI in COVID-19 Compared with Influenza.

Authors:  Bethany C Birkelo; Sharidan K Parr; Amy M Perkins; Robert A Greevy; Juan Pablo Arroyo; Adriana M Hung; Andrew J Vincz; Shailja C Shah; Tarun Kapoor; Michael E Matheny; Edward D Siew
Journal:  Clin J Am Soc Nephrol       Date:  2022-02-02       Impact factor: 10.614

7.  Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19.

Authors:  John A Jarcho; Julie R Ingelfinger; Mary Beth Hamel; Ralph B D'Agostino; David P Harrington
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

8.  CORDITE: The Curated CORona Drug InTERactions Database for SARS-CoV-2.

Authors:  Roman Martin; Hannah F Löchel; Marius Welzel; Georges Hattab; Anne-Christin Hauschild; Dominik Heider
Journal:  iScience       Date:  2020-06-20

9.  Human recombinant ACE2 reduces the progression of diabetic nephropathy.

Authors:  Gavin Y Oudit; George C Liu; Jiuchang Zhong; Ratnadeep Basu; Fung L Chow; Joyce Zhou; Hans Loibner; Evelyne Janzek; Manfred Schuster; Josef M Penninger; Andrew M Herzenberg; Zamaneh Kassiri; James W Scholey
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

Review 10.  Is the kidney a target of SARS-CoV-2?

Authors:  Miguel Angel Martinez-Rojas; Olynka Vega-Vega; Norma A Bobadilla
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.